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sUmmARy – The exact etiology of the conflicting hemostatic disorder in the advanced stage of 
chronic renal disease, i.e. prothrombotic versus bleeding tendency, is not completely understood. Ab-
normal platelet function in patients with renal failure is not caused by high concentrations of urea, al-
though the presence of fibrinogen fragments may prevent binding of normal fibrinogen and formation 
of platelet aggregates. hemostatic abnormalities in end-stage kidney disease may be affected, to some 
extent, by the choice of renal replacement therapy. patients on hemodialysis have an increased risk of 
thrombotic events, primarily due to the release of thromboxane A2 and adenosine diphosphate into the 
circulation, as well as platelet degranulation. some activation of platelets occurs due to the exposure of 
blood to the roller pump segment, but microbubbles may also play a role. Renal transplantation is the 
treatment of choice for patients with end-stage renal disease. Immunosuppressive therapy is associated 
with an increased risk of thromboembolic complications. Additional research is required to identify 
the potential benefits of different immunosuppressive therapies in relation to platelet aggregation, kee-
ping in mind the long term need for immunosuppression in renal transplant patients.
Key words: Platelet aggregation; Kidney failure, chronic; Renal dialysis; Kidney transplantation; Im-
munosuppressive agents
Correspondence to: Prof. Nikolina Bašić-Jukić, department of 
nephrology, Arterial hypertension and dialysis, University de-
partment of Internal medicine, Zagreb University hospital Cen-
ter, Kišpatićeva 12, hR-10000 Zagreb, Croatia
e-mail: nina_basic@net.hr
Introduction
The high mortality rate associated with chronic 
kidney disease (CKd) is mainly due to the increased 
incidence of cardiovascular disease, which contrib-
utes to more than half of deaths in patients with end-
stage renal disease (esRd). Thrombosis is a common 
complication of esRd, particularly in patients on 
hemodialysis. platelet dysfunction, which leads to an 
increased risk of bleeding tendency, also plays an im-
portant role. Thrombotic complications are thought to 
be a net outcome of both underlying kidney disease, 
complicated by renal failure, and its management 
through dialysis or renal transplantation.
In the present paper, we discuss the problems as-
sociated with platelet aggregation in esRd patients 
and renal transplant recipients.
Platelet Aggregation – Normal Clotting Process
hemostasis is the process of blood clot formation 
that maintains the integrity of the circulatory system 
after vascular damage. There are two different and in-
dependent pathways that can activate thrombus for-
mation after the injury:
•	 one	is	exposure	of	the	subendothelial	collagen	
initiating platelet activation, and
•	 the	other	is	initiated	by	tissue	factor	derived	from	
blood vessel wall or present in flowing blood, 
resulting in thrombin formation1. 
Clot formation requires platelet activation and gen-
eration of thrombin and fibrin in good balance with 
Acta Clin Croat,  Vol. 52,  No. 4,  2013 473
Željka martinović et al. Importance of platelet aggregation in patients with end-stage renal disease
plasmin-induced clot lysis2. The first step after vascu-
lar injury is exposure of subendothelial elements such 
as collagen and laminin. platelet glycoprotein receptor 
gp-IV binds collagen and mediates platelet adhesion 
and activation at the site of injury. other glycoprotein 
receptors gp Ib-V-IX interact with collagen-bound 
von willebrand’s factor (vwf), which is also required 
for platelet adhesion.
At the same time, the independent pathway of 
blood coagulation and platelet activation is  initiated 
by tissue factor (tf) released into the circulation after 
vascular damage. platelet activation initiated by this 
pathway does not require disruption of the endothe-
lium and is independent of vwf and glycoprotein VI. 
tissue factor binds to the active factor VIIa forming 
the tf/fVIIa complex initiating a proteolytic cas-
cade.
The final goal is to generate thrombin, which con-
verts fibrinogen to fibrin, but also activates platelets 
by binding to its receptor (protease-activator recep-
tor-1), and results in the release of adenosine diphos-
phate (Adp), serotonin and thromboxane A2. These 
are platelet agonists, which activate other platelets and 
amplify the signal for thrombus formation. The release 
of Adp stimulates platelet activation through two 
Adp receptors, p2y1 and p2y12 (antiplatelet drugs 
directed against these receptors). Thromboxane A2 is 
synthesized in the platelets and functions as platelet 
agonist and vasoconstrictor1.
Clot Lysis – Regulatory Mechanism
The vessel wall with its inner lining of endothe-
lium contains thromboregulators, such as nitric oxide 
(no), prostacyclin and ectonucleotidase, which to-
gether provide defense against thrombus formation. 
prostacyclin is synthesized in the endothelium by 
CoX2 and inhibits platelet aggregation and throm-
boxane A2 mediated vasoconstriction.
nitric oxide is produced by endothelial cells and 
inhibits platelet adhesion and aggregation2. The most 
important inhibitors of the clot formation are anti-
thrombin, tissue factor pathway inhibitor (tfpI), 
protein C and protein s. These inhibitors act in dif-
ferent ways: antithrombin neutralizes enzymes in the 
coagulation cascade (II, IX, X, XII); tfpI inhibits 
factor X and complex tf/fVIIa; and protein C and 
protein s inactivate fVa and fVIIIa.
The most important component of the fibrinolyt-
ic system is the proteolytic enzyme plasmin, which 
cleaves the fibrin degradation products. Its precursor 
plasminogen is synthesized in the liver and can be ac-
tivated by binding to fibrin or tissue plasminogen ac-
tivator (tpA) derived from vascular endothelium. The 
activity of plasmin is regulated by the endothelium, 
which secretes tpA and plasminogen activator inhibi-
tors (pAI-1 and pAI-2)1.
Disorder of Platelet Aggregation in End-Stage 
Renal Disease
Chronic renal failure is characterized by a progres-
sive and irreversible decline in renal function over the 
course of at least 3-6 months. full manifestations of 
the syndrome are seen when the glomerular filtration 
rate (gfR) decreases below 25 ml/min. patients with 
clearance below 10 ml/min (esRd) are dialysis de-
pendent until successful transplantation. dialysis may 
take the form of intermittent hemodialysis using ar-
teriovenous fistula or central venous catheter, or con-
tinuous ambulatory peritoneal dialysis (CApd) via an 
implanted catheter3.
In the advanced stage of chronic renal disease, 
patients suffer from procoagulant abnormalities (im-
paired release of tpA, increased pAI-1, elevated fibrin-
ogen and d-dimer, and increased tf/fVIIa complex) 
leading to excessive cardiovascular events, as well as 
from platelet dysfunction, leading to an increased risk 
of cutaneous, mucosal or serosal bleeding tendency2. 
platelet dysfunctions are observed mainly in advanced 
uremia before starting dialysis treatment4.
several factors contribute to platelet dysfunction 
in patients with esRd, such as impaired function 
of platelet glycoproteins like gpIIb/IIIa and altered 
release of Adp and serotonin from platelet granules, 
which all lead to impaired platelet adhesion and ag-
gregation. Certain uremic toxins such as guanidino-
succinic acid and methyl guanidine may contribute to 
platelet dysfunction by stimulating no release from 
the endothelium, which again inhibits platelet adhe-
sion and aggregation2.
It appears that abnormalities in both the platelets 
and the plasma play a role in subnormal platelet ag-
gregation in uremic state. Urea and other nitrogenous 
compounds such as guanidinosuccinic acid, phenols, 
and a group of substances called uremic middle mole-
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cules have been incriminated in the decreased platelet 
aggregation. however, analysis of a rare syndrome of 
familial azotemia, characterized by high plasma urea 
resulting from impaired urinary excretion but nor-
mal renal function, failed to found any abnormality 
in platelet function. It was concluded that abnormal 
platelet function in patients with renal failure is not 
caused by high concentrations of urea5.
In the normal clotting process, fibrinogen binds to 
the glycoprotein receptor IIb/IIIa complex on the acti-
vated platelet membrane and creates a bridge between 
adjacent platelets. As a result of multiple interactions 
of this type, platelet aggregates are formed. Uremia is 
characterized by the presence of fibrinogen fragments, 
which are not present in normal plasma. These frag-
ments bind to some glycoprotein IIb/IIIa sites on the 
platelet membrane, preventing the binding of normal 
fibrinogen and forming of platelet aggregates6. 
The importance of circulating toxins is based on 
the observed beneficial effect of acute dialysis on 
platelet dysfunction4.
Platelet Aggregation in Hemodialysis Patients and 
Patients on Continuous Ambulatory Peritoneal 
Dialysis (CAPD)
patients on hemodialysis (hd) have an increased 
risk of thrombotic events7. The most common throm-
botic complication in hemodialyzed patients is throm-
bosis of vascular access, which is a major cause of 
hemodialysis-associated morbidity, while cardiovas-
cular and cerebrovascular incidents are major causes 
of dialysis-associated mortality. 
several studies have pointed to inflammation as 
an important contributor to thrombotic complications 
in hemodialyzed patients. Indeed, esRd is currently 
perceived as a state of chronic or recurrent inflam-
mation. furthermore, the inflammatory response is 
exacerbated in hemodialyzed patients as a result of 
bioincompatibility of artificial materials and dialysis 
water. elevated levels of inflammatory mediators and 
acute-phase reactants, such as tumor necrosis fac-
tor (tnf), interleukin-6 (Il-6), C-reactive protein 
(CRp), and fibrinogen have been repeatedly demon-
strated in patients on dialysis. Another contributor to 
dialysis-associated inflammation is complement8.
A comparative study on hemostasis in CApd and 
hd patients observed platelet dysfunction in both 
groups of dialyzed patients that was probably related 
to uremic toxins present in the circulation. It was also 
observed that ristocetin-induced platelet aggregation 
was significantly higher in CApd compared to hd 
patients.
hemodialysis with extracorporeal circulation and 
exposure to heparin may contribute to the prothrom-
botic state due to recurrent platelet stimulation leading 
to their hyperaggregability, reduced levels of heparin 
cofactor II, and increased concentrations of coagula-
tion factors. patients on CApd showed evidence of a 
higher degree of hypercoagulation than hd patients. 
Thus, hemostatic abnormalities in esRd may be af-
fected to some extent by the choice of renal replace-
ment therapy9. 
According to the results of the study that corre-
lated platelet dysfunction and plasminogen levels in 
hd patients, platelet aggregation positively correlat-
ed with plasminogen levels, which were significantly 
lower in hd patients10.
substantial activation of platelets may occur dur-
ing the course of hd. platelet surface markers show 
evidence of platelet degranulation. some activation 
occurs due to exposure of blood to the roller pump 
segment, and micro bubbles may also play a role11.
Results of the investigation of prothrombotic ten-
dency in CApd patients showed that the main rea-
son for the prothrombotic state in these patients was 
chronic activation of coagulation system and elevated 
levels of fibrinogen. The fibrinolytic system and plate-
lets did not contribute to this prothrombotic tenden-
cy12.
Platelet Aggregation in Renal Transplant Patients
The treatment of choice in esRd is kidney trans-
plantation, as it improves survival and quality of life. 
however, the shortage of available donors combined 
with contraindications to transplantation in some 
patients results in the necessity of sustaining these 
persons on dialysis for a variable period of time8. Im-
provements in immunosuppressive therapy have re-
duced early allograft loss due to acute rejection to very 
low levels. early allograft loss due to acute thrombotic 
complications remains a constant and proportionally 
increasing complication of renal transplantation13. 
most people who have a kidney transplant need 
to take at least one immunosuppressive drug for the 
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rest of their lives. Rejection of a kidney is most likely 
to happen within the first 3 months after transplanta-
tion. during this time, people often take a combina-





•	 antiproliferative	 agents	 (such	 as	 azathioprine	 or	
mycophenolate), and
•	 corticosteroids.
maintenance immunosuppressive therapy is ad-
ministered to almost all renal transplant recipients 
to help prevent acute rejection and loss of renal al-
lograft. Although an adequate level of immunosup-
pression is required to damp the immune response to 
the allograft, the level of chronic immunosuppression 
is slowly decreased over time (as the risk of acute re-
jection decreases). 
The optimal maintenance immunosuppressive 
therapy in renal transplantation is not established. The 
major immunosuppressive agents that are currently 
used in various combination regimens are corticos-
teroids (primarily oral prednisone), azathioprine, my-
cophenolate mofetil (mmf), mycophenolate sodium, 
cyclosporine (in standard form or microemulsion), 
tacrolimus, everolimus, and rapamycin (sirolimus)14. 
Immunosuppressants
Immunosuppressive agents are used for induction 
(intense immunosuppression in the initial days after 
transplantation), maintenance, and reversal of estab-
lished rejection14. Azathioprine, which is derived from 
6-mercaptopurine, was the first immunosuppressive 
agent to achieve widespread use in organ transplanta-
tion. Upon the introduction of cyclosporine, azathio-
prine has become a second-line drug14.
Calcineurin inhibitors
Cyclosporine, a cornerstone of immunosuppres-
sion in transplantation, is a prodrug that engages 
cyclophilin, an intracellular protein of the immuno-
philin family, forming a complex that then engages 
calcineurin. The adverse effects of cyclosporine, which 
are related to the concentration of the drug, include 
nephrotoxicity, hypertension, hyperlipidemia, gingi-
val hyperplasia, hirsutism and tremor. Cyclosporine 
can also induce the hemolytic-uremic syndrome and 
post-transplantation diabetes mellitus. Recent devel-
opments include monitoring of the peak cyclosporine 
levels two hours after administration to better reflect 
exposure to the drug.
tacrolimus engages another immunophilin 
(fKBp12) to create a complex that inhibits calcineu-
rin with greater molar potency than does cyclosporine. 
tacrolimus resembles cyclosporine in that it can result 
in nephrotoxicity and the hemolytic-uremic syndrome, 
but it is less likely to cause hyperlipidemia, hyperten-
sion and cosmetic problems, and more likely to induce 
post-transplantation diabetes14.
Inosine monophosphate dehydrogenase inhibitors
mycophenolic acid inhibits inosine monophos-
phate dehydrogenase, a key enzyme in purine synthe-
sis. mycophenolate mofetil is a prodrug that releases 
mycophenolic acid, and in large-scale trials with cy-
closporine, it was superior to azathioprine in prevent-
ing rejection of kidney transplants14.
Target-of-rapamycin inhibitors
sirolimus and everolimus engage fKBp12 to cre-
ate complexes that engage and inhibit the target of ra-
pamycin but cannot inhibit calcineurin. The principal 
nonimmune toxic effects of sirolimus and everolimus 
include hyperlipidemia, thrombocytopenia, and im-
paired wound healing. sirolimus and everolimus may 
reduce cytomegalovirus disease14.
Immunosuppressive Therapy – Platelet Aggregation
Immunosuppressive therapy including cyclosporin 
A is associated with an increased risk of throm-
boembolic complications. It has been reported that 
cyclosporin A enhances platelet aggregation in vitro 
and subsequent thromboxane A2 release, and reduces 
prostacyclin production by the vessel wall15.
Cyclosporine impairs endothelium dependent vas-
orelaxation and decreases prostacyclin (pgI2) release 
from vascular rings and cultured human endothelium. 
pgI2 is synthesized predominantly by cyclooxygenase 
2 (CoX2) in healthy humans. Cyclosporine, but not 
tacrolimus and rapamycin, inhibits CoX2 in human 
vasculature smooth muscle. Rapamycin and tacrolimus 
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may actively suppress platelet and renal thromboxane 
formation. platelet aggregation, thromboxane forma-
tion by activated platelets and renal thromboxane ex-
cretion are lower in patients treated with tacrolimus 
and rapamycin as compared with cyclosporine16. 
According to the results of a study comparing the 
effects of immunosuppressive drugs on platelet aggre-
gation in renal transplant patients, cyclosporine-treat-
ed renal transplant patients showed enhanced platelet 
activation compared with tacrolimus group17.
platelet activity is enhanced in hypercholester-
olemia, which is commonly observed in renal trans-
plant patients. This could be a crucial factor in the 
pathogenesis of atherosclerotic lesion formation and 
cardiovascular events. Activated platelets tend to ag-
gregate and are found close to atherosclerotic plaques. 
The membrane protein p-selectin, which is released 
from endothelial cells and activated platelets, binds 
leukocytes to endothelium and mediates the rosetting 
of activated platelets around neutrophils and mono-
cytes, which could be important in the development 
of atherosclerosis15.
Conclusion
In the advanced stage of chronic renal disease, pa-
tients suffer from procoagulant abnormalities leading 
to excessive cardiovascular events, as well as platelet 
dysfunction, manifested as an increased risk of bleed-
ing tendency. The exact etiology of this conflicting he-
mostatic disorder, i.e. prothrombotic versus bleeding 
tendency, is not completely understood. hemostatic 
abnormalities in esRd may be affected, to some ex-
tent, by the choice of renal replacement therapy (hd 
vs. CApd). The treatment of choice in esRd is renal 
transplantation, which requires permanent need of 
immunosuppression. Immunosuppressive therapy is 
associated with an increased risk of thromboembolic 
complications. It has been reported that cyclosporin 
A, a cornerstone of immunosuppression in transplan-
tation, enhances in vitro platelet aggregation and sub-
sequent thromboxane A2 release, and reduces prosta-
cyclin production by the vessel wall. tacrolimus and 
rapamycin influence platelet aggregation and throm-
boxane formation to lesser extent as compared to cy-
closporine. Additional research is required to identify 
the potential benefits of different immunosuppressive 
drugs in relation to platelet dysfunction, keeping in 
mind the long-term need of immunosuppression in 
renal transplant patients.
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sažetak
ZnAČenJe AgRegACIJe tRomBoCItA U BolesnIKA s BUBReŽnIm ZAtAJenJem
Ž. Martinović, N. Bašić-Jukić, D. Bandić Pavlović i P. Kes
točna etiologija proturječnih hemostatskih poremećaja u terminalnom stadiju bubrežne bolesti, tj. tromboze i sklo-
nosti krvarenju, nije u potpunosti razjašnjena. poremećena funkcija trombocita u bolesnika s bubrežnim zatajenjem nije 
uzrokovana povišenom koncentracijom ureje, premda prisutnost fragmenata fibrinogena može spriječiti vezivanje normal-
nog fibrinogena, odnosno stvaranje agregata tromobocita. na poremećaj hemostaze kod bolesnika s bubrežnim zatajenjem 
može utjecati i izbor nadomjesnog bubrežnog liječenja. Bolesnici na hemodijalizi imaju povećani rizik tromboze prven-
stveno zbog oslobađanja tromboksana A2 i Adp-a u cirkulaciju, kao i zbog degranulacije trombocita. U stanovitoj mjeri 
trombociti se aktiviraju i prolaskom krvi kroz sustav crpki, dok moguću ulogu imaju i mikromjehurići. transplantacija 
bubrega je metoda izbora u liječenju bolesnika s bubrežnim zatajenjem. Imunosupresivna terapija je povezana s povećanim 
rizikom razvoja trombembolijskih komplikacija. Imajući u vidu dugotrajnu potrebu za imunosupresivnim liječenjem kod 
bolesnika s transplantiranim bubregom potrebna su daljnja istraživanja radi utvrđivanja mogućeg povoljnog učinka razli-
čitih imunosupresiva u odnosu na agregaciju trombocita.
Ključne riječi: Trombociti, agregacija; Bubrežno zatajenje, kronično; Bubreg, transplantacija; Imunosupresivi
